Jubilant Therapeutics Announces Oral Presentation of Preliminary Phase 1 Clinical Data for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential Thrombocythemia and Related Myeloproliferative Neoplasms at the 68th ASH Annual Meeting
Abstract data show rapid platelet reductions and durable hematologic control Company to host an event on December 14, 2026 YARDLEY, Pa., Nov. 10, 2026 /PRNewswire/ -- Jubilant Therapeutics, Inc., a clinical-stage biopharmaceutical company, advancing precision therapeutics for...
Covered in this story
Call it yourself
No calls on $JBI yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Janus International Group Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.